Secondary tricuspid regurgitation Do we understand what we would like to treat?

Anne Guérin (1, 2) , Julien Dreyfus (3) , Thierry Le Tourneau (4, 5) , Catherine Sportouch (6) , Olivier Lairez (7) , Jean-Christophe Eicher (8) , Erwan Flécher (1, 2) , Patricia Réant (9) , Erwan Donal (1, 2)

1 LTSI - Laboratoire Traitement du Signal et de l'Image
2 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
3 CCN - Centre cardiologique du Nord
4 ITX-lab - ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291
5 CHU Nantes - Centre Hospitalier Universitaire de Nantes
6 Clinique du Millénaire - Oc Santé [Montpellier]
7 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
8 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
9 CHU Bordeaux

Tricuspid regurgitation has long been a neglected and underestimated entity; its prevalence is significant, and is increasing with the ageing population. Tricuspid regurgitation is often a consequence of chronic left cardiac pathologies or atrial fibrillation. Surgical treatment is recommended for patients with severe symptomatic tricuspid regurgitation or tricuspid annulus dilatation at the time of left heart valve surgery. Secondary tricuspid regurgitation is a complex disease; this review focuses on the need for better understanding of its mechanisms and quantification - mandatory with the advent of new percutaneous treatments.

Mots clés: Pathophysiology; Pathophysiologie; Insuffisance tricuspide; Traitement; Quantification; Treatment; Tricuspid regurgitation

Domaines: Ingénierie biomédicale

Anne Guérin, Julien Dreyfus, Thierry Le Tourneau, Catherine Sportouch, Olivier Lairez, et al.. Secondary tricuspid regurgitation Do we understand what we would like to treat?. Archives of cardiovascular diseases, 2019, 112 (10), pp.642-651. ⟨10.1016/j.acvd.2019.04.010⟩. ⟨hal-02280246⟩